Poolbeg Pharma has secured funding to complete its clinical trials through to the second quarter of 2028. The company is currently recruiting patients for its TOPICAL trial of POLB 001, a drug aimed at preventing cytokine release syndrome in cancer patients, which could enable wider use of immunotherapies outside specialist centers. Additionally, Poolbeg plans to start a proof-of-concept study for an oral GLP-1 obesity treatment later this year. The company has made progress with patents and regulatory agreements, supporting potential multi-billion-dollar sales in the US market.
Poolbeg Pharma's clinical trial funding news comes as Pluang's Health sector shows mixed performance. For readers following Health-sector US stocks on Pluang, here is the market snapshot as of Sep 29, 2026 14:01 WIB: out of 100 priced stocks, 38 rose and 51 fell. Notable movers include TG Therapeutics Inc (TGTX) at USD 56.18 with a -2.18% change and a typical hold time of 15 days, Citius Pharmaceuticals Inc (CTXR) at USD 0.57 with a -2.00% change and 100% buy order activity, and Ascendis Pharma A/S (ASND) at USD 230.06 with a +1.98% change and a typical hold time of 55 days.
The cryptocurrency AAVE surged 9.31% within four hours to reach $163, extending its 24-hour gain to 10.07%. This price increase was accompanied by $140,000 in short liquidations on major exchanges like Binance, Bybit, and OKX, while no long liquidati...
On September 28, all four major crypto spot ETFs—Bitcoin, Ethereum, Solana, and XRP—recorded net inflows totaling about $65 million, highlighting growing institutional demand beyond Bitcoin alone. Bitcoin ETFs led with $31.07 million, followed by Eth...
Genflow Biosciences will present full results from its canine ageing trial at the Animal Longevity Summit in Toronto, highlighting the safety and potential health benefits of its GF-1004 treatment aimed at slowing ageing. The company is also progress...
Bitcoin's price fell below $83,000 on September 28-29, triggering the liquidation of about $500 million in leveraged crypto positions and impacting 129,197 traders. The drop was influenced by rising oil prices after geopolitical tensions and a rare 3...
Telo Genomics announced new clinical research showing its blood-based TELO-MRD test detects residual multiple myeloma cells more sensitively than traditional bone marrow tests like Adaptive clonoSEQ. The TELO-MRD liquid biopsy identifies circulating ...
